Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Quantumscape Corp — how do they compare? Definium Therapeutics Inc. Common Shares trades at $37.05 (market cap $4.59B), while Quantumscape Corp trades at $4.58 (market cap $2.82B). The key difference: Definium Therapeutics Inc. Common Shares is the larger of the two by market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Quantumscape Corp for 37 Days on average.
| DFTX | QS | |
|---|---|---|
Market Cap | $4.59B | $2.82B |
Volume | 2,103,937 | 21,878,246 |
Sector | Health | Consumer Cyclical |
52-Week High | $48.45 | $18.44 |
52-Week Low | $10.68 | $4.52 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $3.55B | $2.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QuantumScape (QS) trades at $4.58, up 1.33% with bearish technical signals and negative profitability metrics. The company remains pre-revenue with significant cash burn, though recent earnings beat expectations. Analyst consensus shows 72.7% hold ratings with a $10.35 price target, while insider selling and delayed commercialization timelines create headwinds.
QS faces substantial execution risk with commercialization not expected until 2029, but maintains automotive partnerships and pilot production progress. The stock trades near 52-week lows, offering potential upside to analyst targets if technology milestones are achieved, though high cash burn and competitive threats remain key concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
